Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

Trial Profile

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
  • Most Recent Events

    • 02 Jul 2019 Status changed from not yet recruiting to recruiting.
    • 18 Mar 2019 Planned End Date changed from 2 Mar 2021 to 29 Mar 2021.
    • 18 Mar 2019 Planned primary completion date changed from 1 Mar 2020 to 26 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top